New KEYTRUDA ® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
Dateline City:
KENILWORTH, N.J. First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 StudyKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that new data investigating the use of KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, in patients with
previously treated advanced urothelial cancer will be presented at the
Society for Immunotherapy of Cancer’s (SITC) 31st Annual
Meeting, Nov. 9-13.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD SITC Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Immunotherapy | Merck